- Home
- XOMA vs MGTX Comparison
XOMA vs MGTX Comparison
Compare XOMA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMA
- MGTX
- Stock Information
- Founded
- XOMA 1981
- MGTX 2015
- Country
- XOMA United States
- MGTX United States
- Employees
- XOMA N/A
- MGTX N/A
- Industry
- XOMA Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XOMA Health Care
- MGTX Health Care
- Exchange
- XOMA Nasdaq
- MGTX Nasdaq
- Market Cap
- XOMA 320.8M
- MGTX 411.4M
- IPO Year
- XOMA N/A
- MGTX N/A
- Fundamental
- Price
- XOMA $28.59
- MGTX $5.98
- Analyst Decision
- XOMA Strong Buy
- MGTX Strong Buy
- Analyst Count
- XOMA 2
- MGTX 2
- Target Price
- XOMA $78.50
- MGTX $22.50
- AVG Volume (30 Days)
- XOMA 18.9K
- MGTX 325.1K
- Earning Date
- XOMA 11-05-2024
- MGTX 11-12-2024
- Dividend Yield
- XOMA N/A
- MGTX N/A
- EPS Growth
- XOMA N/A
- MGTX N/A
- EPS
- XOMA N/A
- MGTX N/A
- Revenue
- XOMA $15,239,000.00
- MGTX $8,122,000.00
- Revenue This Year
- XOMA $456.45
- MGTX $133.83
- Revenue Next Year
- XOMA $29.84
- MGTX $655.34
- P/E Ratio
- XOMA N/A
- MGTX N/A
- Revenue Growth
- XOMA 277.95
- MGTX 26.87
- 52 Week Low
- XOMA $14.27
- MGTX $3.49
- 52 Week High
- XOMA $30.50
- MGTX $7.60
- Technical
- Relative Strength Index (RSI)
- XOMA 53.55
- MGTX 78.17
- Support Level
- XOMA $28.66
- MGTX $3.97
- Resistance Level
- XOMA $30.50
- MGTX $6.24
- Average True Range (ATR)
- XOMA 1.07
- MGTX 0.33
- MACD
- XOMA 0.21
- MGTX 0.20
- Stochastic Oscillator
- XOMA 55.56
- MGTX 88.56
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
About MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.